clinical-trials

I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…

I have the full paper rather than the abstract, and the supplementary appendix. I can predict the outcome but I cannot explain it, which means I will get the next…

The label maximum gets treated as a destination — the "full dose", as though anything below it is partial. But a label maximum is the highest dose a sponsor took…

What I have: vomiting · semaglutide · STEP 1. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

Stated plainly: TRIUMPH-3 · retatrutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…

What I am working with: SURMOUNT-1 · dizziness. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

What I have: FLOW · reflux. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do not…

The case in front of me: semaglutide · minus 20 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at…

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. This is one of those things that everyone repeats and nobody…

The particulars: STEP 5 · nausea. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable with…

What I have: ATTAIN-1 · hair thinning · 36 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

For reference: SURPASS-3 · early satiety · 15 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I keep seeing this stated as a fact with no explanation attached,…

I have been trying to build a spreadsheet of published weight-loss results so I can compare programmes properly, and I keep tripping over the same thing. The primary…

What I am working with: semaglutide · STEP 4. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My…

Conditions: semaglutide · survodutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…

Numbers first: a GLP-1 receptor agonist · semaglutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a…

For reference: semaglutide · cagrilintide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I…

I have the full paper rather than the abstract, and the supplementary appendix. I can do the algebra. I am not confident about the conversion factors. If there is a…

Conditions: hair thinning · semaglutide · FLOW. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

The specifics, since they change the answer: 2 mg · semaglutide. I am at the decision point and I would rather think it through than improvise. I would rather spend…

Concretely: SELECT · fatigue. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change the…

What I am working with: ten weeks · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary…

The case in front of me: hair thinning · semaglutide · STEP 3. I would like to know the limits of what can be inferred from this. What I am trying to avoid is…